Epidemiologia E Possíveis Intervenções Para as Hepatites Virais Em Juiz De Fora, Minas Gerais

Costa, Laura Paranhos Couto da; Fernandes, João Paulo Moreira; Dias, Nikolas Lisboa Coda; Okada, Letícia Martins; Oliveira, Stefan Vilges de

doi:10.36925/sanare.v21i2.1663

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occurrence of outbreaks of hepatitis A in recreational water and drinking water have been constantly reported since it is an enteric virus transmitted by the fecal-oral route in which the ingestion of contaminated water and food or even direct contact with people the person are forms of viral infection. Among the classic symptoms, there is jaundice, choluria and fecal acholia [5,6]. Hepatitis A vaccines are based on classic first-generation inactivated virus vaccines and have been developed by different biopharmaceuticals such as Havrix® (Glaxo Smith Kline Biologicals), Twinrix® also by the same biopharma, but in this case it is a multiple compound vaccine by several immunogens, and the vaccine VAQTA® from the manufacturer Merck & Co.…”

Section: Hepatitis a Virus (Hav)mentioning

confidence: 99%

Immunological serum markers for hepatitis viral infections: HAV, HBV, HCV to advance of genetic engineering

Andressa de Farias Fehlberg,

Joelma Lessa da Silva,

Roberta Pinho Gomes

et al. 2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

Viral hepatitis is increasingly present in infections diagnosed around the world. Thousands of individuals are infected by these often-silent diseases that only manifest themselves when clinical signs are very advanced. Hepatitis A virus (HAV) is a vaccine-preventable liver infection. Recombinant vaccines had been applied with the advance of genetic engineering for HBV. New studies have investigated the improvement of the vaccine model of heterological antigens based on hepatitis B virus envelope protein containing HCV antigen as a chimeric vaccine. The aim of this study was to evaluate the detection rates of these viruses that induce liver damage and can progress to cancer depending on the associated epigenetic factors. Thus, between January 10, 2022, and March 31, 2023, about 2.750 samples were collected from 2.713 patients, of which 38.43% were for HCV and 30.25% for HAV research. For HBV, it had been analyzed about 2.222 samples from 1.660 patients, which females were more prevalent (60.60%) and males (39.39%). In all, eight biomarkers of the HBV were investigated and HBsAg marker was non-reactive in 44.01% of the total samples analyzed and 31,41% reactive for anti-HBs. HBV/HCV coinfected patients need more attention. New research about immunological serum markers should be better investigated to correlation the natural history of hepatitis viral infections and hepatocellular carcinoma (HCC) improve tumour genomic and epidemiological surveillance in clinical trials.

show abstract

Section: Hepatitis a Virus (Hav)mentioning

confidence: 99%

Immunological serum markers for hepatitis viral infections: HAV, HBV, HCV to advance of genetic engineering

Andressa de Farias Fehlberg,

Joelma Lessa da Silva,

Roberta Pinho Gomes

et al. 2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…The occurrence of outbreaks of hepatitis A in recreational water and drinking water have been reported since it´s an enteric virus transmitted by the fecal-oral route in which the ingestion of contaminated water and food or even direct contact with people the person are forms of viral infection. Among the classic symptoms, there is jaundice, choluria and fecal acholia [2,3,4].…”

Section: Hepatitis a Virus (Hav)mentioning

confidence: 99%

Outbreak-Associated Cases Of Human Hepatitis Viruses (HAV, HBV & HCV) With Herpes Simplex Virus And HIV Infections Detected in Blood-Based Biomarkers

Fehlberg,

Simões,

Gomes

et al. 2023

BJMAS

View full text Add to dashboard Cite

Hepatitis A vaccines are based on classic first-generation inactivated virus vaccines and have been developed by different biopharmaceuticals. HAV is found in the stool, blood of people who are infected and foodborne hepatitis. HBV is a short-term disease and is one of the major causative agents of chronic liver illness. For others, it can become a long-term, chronic infection like liver disease or liver cancer. The analysis of genomic variability of HBV isolates is fundamental for molecular and epidemiological studies. HCV has a higher rate of mutation existing inside an individual as quasispecies. In this sense, this study addresses an analysis of viral hepatitis A/B/C, Herpervirus Simplex (HSV) type 1/2 and the human immunodeficiency virus (HIV) as topics related to comprehensive care for people with sexually transmitted infections (STIs). A total of 2.750 samples were collected from 2.713 patients, of which 38,43% were for HCV; 31,20% for HIV research; 30,25% for HAV and 0,10% for HSV. In all, eight biomarkers of the hepatitis B virus (HBV) were investigated, of which the HBsAg marker was non-reactive in 44,01% (2022 y) and 47.66% (2023 y). About 31,41% (2022 y) and 31.99% (2023y) were reactive for anti-HBs. The highest percentage of investigated samples (98.38%) was recorded in March 2022 with a average proportion of 55.25 ± 12.96 (CV = 0.234) for the non reactive IgM biomarker. The authors suggest follow-up with new serological research associated with molecular assays aimed specifically at reactive and inconclusive results.

show abstract

Epidemiologia E Possíveis Intervenções Para as Hepatites Virais Em Juiz De Fora, Minas Gerais

Cited by 2 publications

References 4 publications

Immunological serum markers for hepatitis viral infections: HAV, HBV, HCV to advance of genetic engineering

Immunological serum markers for hepatitis viral infections: HAV, HBV, HCV to advance of genetic engineering

Outbreak-Associated Cases Of Human Hepatitis Viruses (HAV, HBV & HCV) With Herpes Simplex Virus And HIV Infections Detected in Blood-Based Biomarkers

Contact Info

Product

Resources

About